Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALID II: PK of Valacyclovir Oral Solution in Children
NCT04081480Phase 2Terminated
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2019
- Primary completion
- May 2021
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of valaciclovir in herpes simplex virus infection and varicella zoster virus infection, sponsored by Radboud University Medical Center. Primary endpoints: Area under the curve at 12 hours, Maximum Plasma Concentration at 12 hours and 2 more. Started Dec 2019; status: terminated.
02
Drugs
valaciclovir
03
Conditions
herpes simplex virus infectionvaricella zoster virus infection
Beyond the preview
Go deeper on NCT04081480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04081480.